Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.
Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.
Estimated reading time: 2 min
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
If you are interested in learning more about how to protect yourself, visit the FCA’s website here.